Health Care • Biotechnology: Pharmaceutical Preparations
$20.44 ▼ -1.07
(-4.97%)
MKT CAP: $7.49B • VOL: 5.02M
52W L $11 52W H $22
AMRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.02B | $2.79B | $2.39B |
| YoY Revenue Growth % | +8.0% | +16.7% | — |
| Gross Profit | $1.11B | $1.02B | — |
| Gross Margin % | 36.9% | 36.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $394.1M | $249.3M | $204.4M |
| Operating Margin % | 13.1% | 8.9% | 8.5% |
| Net Income (GAAP) | $72.1M | -$116.9M | -$84.0M |
| EBITDA (Normalized) | $450.1M | $290.9M | $290.5M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $340.0M | $295.1M | $345.6M |
| Capital Expenditures (CapEx) | $70.1M | $51.9M | $107.7M |
| Free Cash Flow (FCF) | $269.9M | $243.2M | $237.9M |
| FCF Margin % | 8.9% | 8.7% | 9.9% |
| Return on Invested Capital (ROIC %) | 14.1% | 10.1% | 6.5% |
| Cash & Short-Term Equivalents | $282.0M | $110.6M | — |
| Total Debt (Short + Long Term) | $2.57B | $2.16B | $957.0M |
| Total Stockholders' Equity | -$70.8M | -$109.3M | $1.96B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AMRX.